HLA-DRB1: A Drug Target / Disease Biomarker (G3123)

Target Name: HLA-DRB1

NCBI ID: G3123

HLA-DRB1

HLA-DRB1: A Drug Target / Disease Biomarker

HLA-DRB1 is a human leukocyte antigen (HLA) gene that is located on the X chromosome and is responsible for the production of the DRB1 antigen. HLA-DRB1 is a key component of the immune system and plays a crucial role in the regulation of immune responses. Unfortunately, HLA-DRB1 has also been implicated in the development of certain diseases, including cancer. As a result, HLA-DRB1 has become a drug target of interest for researchers and pharmaceutical companies.

HLA-DRB1 is a transmembrane protein that consists of a pre-尾 chain and a post-尾 chain. The pre-尾 chain consists of the constant region, which is responsible for maintaining the structural integrity of the protein, while the post-尾 chain consists of the variable regions, which are responsible for the recognition of foreign antigens by the immune system.

HLA-DRB1 is a key regulator of immune responses and is involved in the development and regulation of CD4+ and CD8+ T cells. CD4+ T cells are responsible for cell-mediated immunity, while CD8+ T cells are responsible for cell-mediated immunity and for the regulation of inflammation. HLA-DRB1 is required for the development and function of CD4+ T cells and is also involved in the regulation of CD8+ T cell responses.

HLA-DRB1 has also been implicated in the development of certain diseases, including cancer. For example, studies have shown that HLA-DRB1 is often expressed in tissues from patients with melanoma, a type of skin cancer. Additionally, HLA-DRB1 has been shown to be involved in the regulation of immune responses in individuals with autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis.

As a result, HLA-DRB1 has become a drug target of interest for researchers and pharmaceutical companies because of its involvement in the immune system and its potential role in the development of certain diseases. HLA-DRB1 has also been shown to be a potential biomarker for certain diseases, such as cancer.

HLA-DRB1 has also been the focus of research into the use of drugs that target the protein. For example, a drug called BK-421 has been shown to inhibit the activity of HLA-DRB1 and has been shown to have potential as a treatment for certain diseases. Additionally, a drug called Oprozomib has been shown to inhibit the activity of HLA-DRB1 and has been shown to have potential as a treatment for certain diseases.

In conclusion, HLA-DRB1 is a human leukocyte antigen that is located on the X chromosome and is responsible for the production of the DRB1 antigen. HLA-DRB1 is a key component of the immune system and plays a crucial role in the regulation of immune responses. Its involvement in the development of certain diseases, including cancer, has made it a drug target of interest for researchers and pharmaceutical companies. Additionally, HLA-DRB1 has also been shown to be a potential biomarker for certain diseases. Further research is needed to fully understand the role of HLA-DRB1 in the immune system and its potential as a drug target.

Protein Name: Major Histocompatibility Complex, Class II, DR Beta 1

Functions: A beta chain of antigen-presenting major histocompatibility complex class II (MHCII) molecule. In complex with the alpha chain HLA-DRA, displays antigenic peptides on professional antigen presenting cells (APCs) for recognition by alpha-beta T cell receptor (TCR) on HLA-DRB1-restricted CD4-positive T cells. This guides antigen-specific T-helper effector functions, both antibody-mediated immune response and macrophage activation, to ultimately eliminate the infectious agents and transformed cells (PubMed:29884618, PubMed:22327072, PubMed:27591323, PubMed:8642306, PubMed:15265931, PubMed:31495665, PubMed:16148104). Typically presents extracellular peptide antigens of 10 to 30 amino acids that arise from proteolysis of endocytosed antigens in lysosomes (PubMed:8145819). In the tumor microenvironment, presents antigenic peptides that are primarily generated in tumor-resident APCs likely via phagocytosis of apoptotic tumor cells or macropinocytosis of secreted tumor proteins (PubMed:31495665). Presents peptides derived from intracellular proteins that are trapped in autolysosomes after macroautophagy, a mechanism especially relevant for T cell selection in the thymus and central immune tolerance (PubMed:17182262, PubMed:23783831). The selection of the immunodominant epitopes follows two processing modes: 'bind first, cut/trim later' for pathogen-derived antigenic peptides and 'cut first, bind later' for autoantigens/self-peptides (PubMed:25413013). The anchor residue at position 1 of the peptide N-terminus, usually a large hydrophobic residue, is essential for high affinity interaction with MHCII molecules (PubMed:8145819)

The "HLA-DRB1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HLA-DRB1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets